Compliance

Pharmacy Practice & Law: The Top 10+ Stories of 2026 Thus Far

As we navigate through the rough seas of healthcare in 2026, the ocean itself is undergoing a massive structural shift. Between revolutionary regulatory...

Editorial illustration of balanced scales representing pharmacy law and patient care.
Share In f X @
From the Magazine
This story appears in the November–December 2026 issue of Dispense Times.

As we navigate through the rough seas of healthcare in 2026, the ocean itself is undergoing a massive structural shift. Between revolutionary regulatory actions, landmark ERISA litigation, and realignments in reimbursement models, our daily practice at the counter and in health systems is changing rapidly.

Below is the updated top 10 list of the biggest pharmacy and pharmacy law stories that have shaped our profession so far this year, at least in my own corner of pharmacy practice, complete with forward-looking predictions for what lies ahead – and the predictions are mine alone and purely speculative, not necessarily those of my employer, and certainly not set in stone.

1. Landslide FTC Consent Orders & Legal Settlements Dismantle Legacy PBM Rebate Structures

The Federal Trade Commission (FTC) achieved landmark consent agreements with major pharmacy benefit managers (PBMs), resolving long-standing administrative cases.

  • The Impact: The settlements directly target anti-competitive pricing, eliminating spread pricing models and delinking manufacturer group purchasing organization (GPO) fees from drug list prices. Future Prediction: By late 2027, traditional spread pricing will be rendered obsolete across commercial lines, forcing PBMs to pivot entirely toward fee-for-service administrative models.
  • Pharmacy Operations: PBMs are now required to offer contracted retail community pharmacies an opt-in cost-plus reimbursement model (actual acquisition cost plus a defined dispensing fee). This offers an immediate alternative to underwater MAC lists that have strained independent operations for years. Future Prediction: At least 60% of independent community pharmacies will migrate to standardized cost-plus contracts by mid-2027, stabilizing net operating margins across independent retail.

2. CMS “Maximum Fair Price” Takes Effect for Initial 10 Negotiated Part D Drugs

January 1, 2026, marked a major milestone under the Inflation Reduction Act as the first batch of 10 Medicare Part D negotiated drugs reached their effective “Maximum Fair Price” (MFP) dates.

  • Key Agents Affected: High-utilization maintenance therapies including Eliquis, Jardiance, Farxiga, Entresto, NovoLog/Fiasp, and Januvia. Future Prediction: CMS will expand the MFP negotiation list to include up to 15 additional high-cost specialty biologics in the next budget cycle, driving further manufacturer price compression.
  • The Clinical & Financial Friction: While patient out-of-pocket costs at the register have dropped significantly, pharmacies are managing inventory devaluations, gross margin shifts, and tight reconciliation windows with drug wholesalers as statutory pricing filters through commercial formularies. Future Prediction: Wholesalers will implement automated real-time price-reconciliation software by Q1 2027 to eliminate the 60-day cash-flow lag currently plaguing community pharmacy inventory balances.

3. Federal Launch of TrumpRx.gov Expands Traditional Direct-to-Consumer Distribution

The launch of the federal government’s TrumpRx.gov platform established a unified digital portal connecting cash-paying patients directly to manufacturer-based direct-to-consumer (DTC) models and cash discount programs for consumers without insurance, or underinsured, like with Mark Cuban Cost Plus Drug’s local pickup option, TeamCubanCard.com and Costplusdrugs.com mail order DTC program.

  • The Reality at the Counter: Driven primarily by high demand for GLP-1 and anti-obesity medications, patients are increasingly bypassing traditional plan insurance in favor of direct-from-manufacturer cash options. Future Prediction: Direct-to-consumer cash transactions will capture over 20% of total outpatient GLP-1 and metabolic prescription volume by the end of 2027.
  • The Pharmacist’s Duty: Community pharmacists are acting as financial navigation counselors, verifying whether DTC purchases or traditional insurance best serve the patient’s long-term deductible and out-of-pocket maximum targets. Future Prediction: Retail pharmacies will integrate automated cash-versus-insurance copay evaluation tools into their dispensing systems to streamline financial counseling at the point of sale.

4. Enactment of the Consolidated Appropriations Act of 2026 Imposes Strict Federal PBM Audits

Congress passed the Consolidated Appropriations Act (CAA) of 2026, bringing aggressive statutory rules to PBM administration.

  • Rebate Pass-Through Mandate: PBMs are now federally required to pass through 100% of drug rebates received directly to health plan sponsors, providing detailed quarterly spend reporting. Future Prediction: Quarterly rebate auditing will become standard practice for self-funded employers, leading to the recovery of billions in misallocated pharmacy spend by 2028.
  • Audit Protections: The law restricts arbitrary PBM audit frequency and retroactive clawback mechanisms against dispensaries, providing community and health-system pharmacies with critical administrative relief. Future Prediction: The reduction in retroactive recoupments will lower administrative overhead for community dispensaries, decreasing pharmacy audit-defense expenditures by 40%.

5. Courts Target ERISA Fiduciary Breaches: Progeny of Plan Sponsor & PBM Drug Pricing Suits

A wave of high-profile ERISA class-action lawsuits—led by the progeny of Lewandowski v. Johnson & Johnson and follow-on participant suits against plan sponsors like JPMorgan and Wells Fargo—has put employer health plans under intense federal court scrutiny. We wrote about this earlier this year and you can read about the cases here.

  • The Allegations: Plaintiffs contend that employer plan sponsors breached their Employee Retirement Income Security Act (ERISA) fiduciary duties of prudence and loyalty by failing to monitor their PBM contract terms. Cases cite egregious examples of plans paying thousands of dollars for generic specialty drugs (such as teriflunomide) through PBM-affiliated mail-order pharmacies when retail cash prices were a fraction of the cost. Future Prediction: A majority of top-tier Fortune 500 employers will systematically terminate traditional PBM contracts over the next two years in favor of pass-through transparent brokers to mitigate legal liability.
  • Legal Turning Point: Federal courts are increasingly allowing “prohibited transaction” claims to survive motions to dismiss where plan fiduciaries permitted unreasonable PBM compensation and retained spread pricing. Future Prediction: A binding appellate or Supreme Court ruling within 18 months will establish mandatory benchmark standards for employer health plan drug procurement.
  • The Pharmacy Outcome: Plan fiduciaries are now actively stripping PBMs of opaque pricing structures, demanding pass-through models, and auditing specialty mail-order steering to shield themselves from participant litigation—creating a direct market push toward transparent pharmacy contracting. Future Prediction: Independent and community pharmacies will capture significant market share as employer health plans eliminate mandatory PBM mail-order exclusivity clauses.

6. States Begin Directing Limits on Vertically Integrated Pharmacies/PBMs

State legislatures across the country have shifted from basic transparency mandates to structural separation laws, disallowing vertically integrated PBMs from simultaneously operating both as claims processors/adjudicators and pharmacy owners within the same jurisdiction.

  • The “Choose Your Function” Mandate: Laws passed in pioneering states force conglomerate healthcare entities to select a single operational role within the state border—they must either act exclusively as a licensed PBM/plan administrator or operate retail/mail-order/specialty pharmacies, but strictly not both. Future Prediction: Conglomerate health entities will be forced to spin off their retail pharmacy divisions or exit PBM claims management in up to a dozen states by 2028.
  • Arkansas (Act 624 / HB 1150): As the first state to enforce this statutory ban, Arkansas prohibited PBMs from directly or indirectly holding a pharmacy license. This forced major vertically integrated entities to evaluate structural divestitures or risk losing state pharmacy licensure. Future Prediction: Arkansas’s law will withstand initial federal court appeals, prompting a domino effect of similar legislation across neighboring Southern and Midwestern states.
  • Tennessee (FAIR Rx Act / SB 2040): Following Arkansas, Tennessee enacted legislation establishing strict structural separation between insurer/PBM operations and pharmacy ownership, setting firm sunset timelines for integrated PBMs to divest in-state specialty and retail dispensaries. Future Prediction: National PBM-owned specialty pharmacies will sell or transition their local Tennessee dispensaries to regional health-system specialty networks before the statutory deadline.
  • Contagion Across State Lines: Model legislation introduced in states like Texas, Vermont, and New York explicitly restricts state contracting and commercial licensure for entities operating dual PBM-pharmacy roles, targeting the self-dealing and preferential network steering that previously disadvantaged independent and health-system pharmacies. Future Prediction: A unified coalition of state attorneys general will initiate joint antitrust enforcement actions targeting multi-state vertical integration in pharmacy supply chains.

7. CMS Launches the 340B Rebate Model Pilot Program

January saw the official rollout of the Centers for Medicare & Medicaid Services (CMS) 340B Rebate Model Pilot, covering Medicare Drug Price Negotiated products.

  • Operational Shift: Moving away from traditional upfront 340B drug discounts, covered entities and contract pharmacies must now transition to a retrospective rebate model. Future Prediction: The retrospective model will cause temporary working-capital shortfalls for safety-net hospitals, accelerating liquidity challenges through 2027.
  • Health-System Impact: The shift increases administrative burden, requiring pharmacy operations teams to implement robust tracking and post-dispense claim submissions to ensure 340B revenue realization while preventing duplicate discounting. Future Prediction: Third-party 340B technology vendors will rapidly introduce AI-driven claims-clearing platforms to automate retrospective rebate collection and minimize administrative friction.

8. Open Transparent and Cost-Plus Models Reset Payment and Reimbursement Methodologies (The MCCPDC Effect)

Transparent pricing models have fully crossed over from niche alternative cash channels into core health-system and enterprise procurement strategies, driven largely by the Mark Cuban Cost Plus Drug Company (MCCPDC).

  • The MCCPDC Blueprint: By publishing the baseline manufacturing acquisition cost and adding a strict, transparent fee structure—a 15% markup + fixed dispensing fee + shipping—MCCPDC proved that transparency is viable and profitable. Future Prediction: Cost-plus pricing benchmarks will become the standard pricing reference point in over 50% of commercial self-insured health plans by 2028.
  • Institutional Integration: MCCPDC created the Cost Plus Drugs Marketplace to support its pharmacy network and other licensed facilities across the US with supplying other drugs B2B via wholesalers integrated to Marketplace. This supports not drowning retail pharmacies in under water reimbursements, and all licensed facilities including hospitals and clinics. And, MCCPDC’s sterile fill finish facility in Dallas supports by offering another alternative for injectables on the FDA drug shortages list. Future Prediction: Health-system purchasing networks will shift up to 20% of their generic sterile injectable volume directly to transparent alternative manufacturers to buffer against drug shortages.
  • Market-Wide Shift: This “cost-plus” methodology has forced major retail chains, health systems, and payors to establish their own transparent cost-plus reimbursement frameworks, effectively resetting how drug value and dispensing fees are calculated across the entire supply chain. Future Prediction: Traditional Average Wholesale Price (AWP) and other “average” pricing metrics will be phased out of commercial pharmacy contracts in favor of transparent Acquisition Cost indices by the end of the decade.

9. State Legislatures Push Total Prohibition of PBM Self-Steerage to Health-System Pharmacies

Over 40 states introduced or expanded legislation targeting anti-competitive PBM practices, with a major emphasis on eliminating patient self-steerage.

  • State vs. Payor Battle: New state mandates strictly prohibit PBMs from forcing patients to use PBM-owned mail-order or specialty pharmacies. State pharmacy boards are aggressively auditing payors that deny network access to health-system integrated specialty pharmacies, restoring patient choice for complex specialty drug management. Future Prediction: Health-system integrated specialty pharmacies will double their capture rate of complex oncology and immunology patients within their health systems over the next three years.

10. Mark Cuban Expands Beyond Pharmacy: Cost Plus Wellness Launches to Target Medical Costs

Building on his disruption of the pharmaceutical supply chain, Mark Cuban officially expanded into broader healthcare delivery with the launch of CostPlusWellness.com.

  • Direct Employer-Provider Contracting: Cost Plus Wellness operates as an open-source initiative and direct-contracting clearinghouse connecting self-funded employer health plans directly with healthcare providers, surgical centers, and Direct Primary Care (DPC) networks. Future Prediction: Direct employer-provider contracting platforms will bypass traditional health insurance networks for up to 20% of elective outpatient procedures by 2028.
  • Bypassing the Insurance Middleman: Just as Cost Plus Drugs eliminated traditional PBM spread pricing, Cost Plus Wellness publishes fully transparent, un-redacted contracts with upfront, cash-based medical procedure pricing. It eliminates secret insurer-carrier discounts, hidden administrative fees, and complex claims processing. Future Prediction: Upfront cash pricing for outpatient medical procedures will reduce administrative claims-processing costs for participating providers by over 30%.
  • The Pharmacist & Health-System Dynamic: For outpatient clinics, health-system outpatient centers, and ambulatory surgery centers (ASCs), this framework offers direct cash reimbursement without carrier denial risk. Pharmacists integrated into primary care clinics (such as DPC practices) benefit directly as these transparent medical models bypass traditional insurer prior authorizations and embed comprehensive pharmacy management into flat-rate primary care packages. Future Prediction: Embedded clinical pharmacists within Direct Primary Care clinics will see expanded prescriptive authority and fee-for-service reimbursement through flat-rate employer health plans by late 2027, and the last 5 feet between the pharmacist and the patient, will become a primary care zone in addition to traditional dispensing functions for community pharmacies, particularly in rural and underserved settings.

11. Bonus: The top story that no one paid attention to but should have: The Complexity of Moving One Electronic Commercial Prescription Through the Background Electronic Superhighway—and Who Controls the Traffic.

Of all the stories of 2026 we paid attention to, this one received the least amount of press.

  • Yet, what is happening to our prescriptions behind the scenes—who controls the information and data, how prescriptions move, and who influences that movement—is becoming increasingly important to understand in pharmacy practice.
  • Now that electronic prescribing is mandated in several states, we need to start paying attention to how prescriptions move and asking tougher questions about who has access to the data, why prescriptions move the way they do, and how those electronic pathways can ultimately affect payment and reimbursement. We covered the journey of a commercial prescription late in 2026, and it is worth a read, albeit mind-bending. Future Prediction: Prescription routing will become a competitive battleground as control over the electronic pathway increasingly means influence over where prescriptions go, how claims move, and ultimately how pharmacies are reimbursed.

As the curse states: “May you live in interesting times.” And now having served the profession of pharmacy for decades, the only certainty as we move into 2027 is more…change. May the change be better for our patients, and for our profession. 💊

This article was co-produced by AI and the author. Opinions/predictions are the author’s at the time this article was drafted and purely speculative.

Dispense Times

Get every issue, free

Practical ideas for independent pharmacy owners, delivered to your inbox.

Subscribe to the digital magazine

Newsletter

Independent pharmacy intelligence in your inbox.

News, analysis, and partner resources for pharmacy decision makers.